Cooper Companies (NASDAQ:COO) Announces Earnings Results, Beats Expectations By $0.11 EPS

Cooper Companies (NASDAQ:COO) announced its earnings results on Thursday. The medical device company reported $1.21 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.10 by $0.11, FiscalAI reports. The business had revenue of $1.08 billion for the quarter, compared to analyst estimates of $1.06 billion. Cooper Companies had a net margin of 5.57% and a return on equity of 10.85%. The company’s revenue for the quarter was up 7.9% compared to the same quarter last year. During the same period last year, the firm posted $0.96 earnings per share. Cooper Companies updated its FY 2026 guidance to 4.580-4.660 EPS.

Here are the key takeaways from Cooper Companies’ conference call:

• Record Q2 results came in ahead of expectations, with revenue up 8% to $1.08 billion and non-GAAP EPS up 26% to $1.21, marking the company’s tenth straight quarter of beating consensus.
• CooperSurgical strategic review is advancing after settlements resolved substantially all embryo media recall claims, and management said it is now in active discussions with multiple interested parties about the business.
• CooperVision strength was offset by Asia-Pac weakness: Americas and EMEA grew well, but Asia-Pac declined as the company continued to rationalize legacy hydrogel products and faced softer demand in Japan and China.
• Fertility performed strongly, with CooperSurgical fertility revenue up 10% organically, driven by capital equipment, RI Witness, and broader product demand; management expects mid-single-digit growth in the back half of the year.
• Free cash flow outlook improved to about $650 million for fiscal 2026, supported by inventory reductions from a new AI-based control system, though gross margins are expected to face pressure from FX, tariffs, freight, and lower production.

Cooper Companies Price Performance

COO opened at $67.34 on Friday. The stock has a market capitalization of $13.14 billion, a PE ratio of 57.07, a P/E/G ratio of 1.74 and a beta of 0.87. Cooper Companies has a 1 year low of $58.89 and a 1 year high of $89.83. The company has a debt-to-equity ratio of 0.22, a quick ratio of 0.79 and a current ratio of 1.34. The company’s 50 day simple moving average is $65.09 and its 200 day simple moving average is $74.52.

More Cooper Companies News

Here are the key news stories impacting Cooper Companies this week:

• Positive Sentiment: Cooper Companies posted better-than-expected Q2 results, with EPS of $1.21 topping estimates of $1.10 and revenue of $1.08 billion beating forecasts, while sales rose 7.9% year over year. CooperCompanies Announces Second Quarter 2026 Results
• Positive Sentiment: Management said it reached agreements to resolve substantially all claims tied to the prior fertility media recall, reducing a major legal overhang and supporting investor confidence in the company’s outlook. QuiverQuant article
• Positive Sentiment: Needham reaffirmed a Buy rating on COO and lowered its price target to $86, still implying meaningful upside from current levels. TipRanks analyst update
• Positive Sentiment: Stifel, Baird, and JPMorgan all cut price targets but kept constructive ratings, suggesting analysts see the report as solid even after valuation resets. Benzinga analyst update
• Neutral Sentiment: The company guided FY2026 EPS to $4.58-$4.66, slightly around consensus, which helps confirm expectations but does not point to a major near-term surprise. Earnings report transcript
• Negative Sentiment: JPMorgan lowered its price target on COO from $80 to $71 and kept a Neutral rating, reflecting more cautious expectations despite the stock’s recent strength. JPMorgan price target update

Institutional Inflows and Outflows

A number of large investors have recently modified their holdings of COO. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its holdings in shares of Cooper Companies by 48.9% in the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 22,407 shares of the medical device company’s stock valued at $1,890,000 after buying an additional 7,363 shares in the last quarter. First Trust Advisors LP grew its holdings in shares of Cooper Companies by 115.8% in the 2nd quarter. First Trust Advisors LP now owns 136,334 shares of the medical device company’s stock worth $9,702,000 after acquiring an additional 73,165 shares during the last quarter. Cresset Asset Management LLC acquired a new position in shares of Cooper Companies in the 2nd quarter worth $291,000. Cerity Partners LLC raised its position in shares of Cooper Companies by 4.4% during the second quarter. Cerity Partners LLC now owns 17,870 shares of the medical device company’s stock worth $1,272,000 after purchasing an additional 757 shares during the period. Finally, Daiwa Securities Group Inc. raised its position in shares of Cooper Companies by 2.8% during the second quarter. Daiwa Securities Group Inc. now owns 35,839 shares of the medical device company’s stock worth $2,551,000 after purchasing an additional 973 shares during the period. 24.39% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

Several analysts have recently commented on the company. JPMorgan Chase & Co. cut their price target on shares of Cooper Companies from $80.00 to $71.00 and set a “neutral” rating for the company in a report on Friday. KeyCorp restated a “sector weight” rating on shares of Cooper Companies in a research report on Friday. Wells Fargo & Company reaffirmed a “sell” rating and issued a $66.00 target price (down from $82.00) on shares of Cooper Companies in a report on Friday. Needham & Company LLC reduced their price target on shares of Cooper Companies from $101.00 to $86.00 and set a “buy” rating for the company in a research report on Friday. Finally, Citigroup reissued a “neutral” rating and set a $69.00 price target (down from $80.00) on shares of Cooper Companies in a research note on Thursday, May 28th. One investment analyst has rated the stock with a Strong Buy rating, eight have assigned a Buy rating, six have issued a Hold rating and two have issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, Cooper Companies has a consensus rating of “Hold” and a consensus target price of $82.64.

About Cooper Companies

Cooper Companies, Inc (NASDAQ: COO) is a global medical device company headquartered in San Ramon, California. Founded in 1958, the company has grown through strategic acquisitions and organic development to become a major provider of vision care and women’s health products. Cooper Companies operates through two primary business segments—CooperVision and CooperSurgical—each serving specialized markets within the healthcare industry.

The CooperVision segment develops, manufactures and markets a broad range of soft contact lenses, as well as related accessories.